丁苯酞注射液联合替格瑞洛片、阿司匹林肠溶片治疗急性脑梗死患者的临床研究  

Clinical Study on Butylphthalide Injection Combined with Ticagrelor Tablets and Aspirin Enteric-Coated Tablets in the Treatment of Patients with Acute Cerebral Infarction

作　　者：季正栋 杨浩 苏丹[1] 徐君 JI Zheng-dong;YANG Hao;SU Dan;XU Jun(Department of Pharmacy,The Third Affiliated Hospital of Nanjing Medical University(The Second People's Hospital of Changzhou),Changzhou,Jiangsu,213000,China;Department of Neurology,The Third Affliated Hospital of Nanjing Medical University(The Second People's Hospital of Changzhou),Changzhou,Jiangsu,213000,China)

机构地区：[1]南京医科大学第三附属医院(常州市第二人民医院)药学部,江苏常州213000 [2]南京医科大学第三附属医院(常州市第二人民医院)神经内科,江苏常州213000

出　　处：《现代生物医学进展》2025年第4期713-719,共7页Progress in Modern Biomedicine

基　　金：江苏省药学会-恒瑞医院药学科研项目(H2021030)。

摘　　要：目的:探讨丁苯酞注射液联合替格瑞洛片、阿司匹林肠溶片治疗急性脑梗死(ACI)患者的临床疗效.方法:采用随机数字表法产生随机数字,再用信封法随机将98例ACI患者分为对照组(接受替格瑞洛片、阿司匹林肠溶片治疗,n=49)和研究组(对照组基础上接受丁苯酞注射液治疗,n=49).对比两组临床总有效率、美国国立卫生研究院卒中量表(NIHSS)评分、血清炎症介质[C-反应蛋白(CRP)、白细胞介素-6(IL-6)、同型半胱氨酸(Hcy)]、简易智能精神状态检查量表(MMSE)评分及不良反应总发生率.结果:治疗后,研究组的临床总有效率为45例(91.84%),高于对照组的36例(73.47%)(P<0.05);两组MMSE评分升高,NIHSS评分下降,且研究组的变化幅度大于对照组(P<0.05).两组血清CRP、Hcy、IL-6水平下降,研究组的变化幅度大于对照组(P<0.05).两组不良反应总发生率无差异(P>0.05).结论:丁苯酞注射液联合替格瑞洛片、阿司匹林肠溶片治疗ACI患者,可提高临床疗效,减轻脑损伤,降低炎症介质水平,且具有较高的安全性.Objective:To investigate the clinical efficacy of butylphthalide injection combined with tica grelor tablets and aspirin enteric-coated tablets in the treatment of patients with acute cerebral infarction(ACI).Methods:Random numbers were generated by random number table method,and 98 patients with ACI were randomly divided into control group(received ticagrelor tablets and aspirin enteric-coated tablets,n=49)and study group(received butylphthalide injection on the basis of control group,n=49).The total clinical effective rate,National Institutes of Health Stroke Scale(NIHSS)score,serum inflammatory mediators[C-reactive protein(CRP),interleukin-6(IL-6),homocysteine(Hcy)],Mini-Mental State Examination(MMSE)score,and total incidence of adverse reactions were compared between two groups.Results:Post-treatment,the total effective rate 45 cases(91.84%)of the study group was higher than that 36 cases(73.47%)of the control group(P<0.05).MMSE score increased,NIHSS score decreased,and the change range of the study group was greater than the control group(P<0.05).Serum CRP,Hcy and IL-6 levels were decreased in both groups,and the changes in the study group were greater than the control group(P<0.05).There was no difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Butylphthalide injection combined with ticagrelor tablets and aspirin enteric-coated tablets in the treatment of ACI patients,which can improve the clinical efficacy,reduce brain injury,reduce the level of inflammatory factors,and have high safety.

关 键 词：丁苯酞注射液 替格瑞洛片 阿司匹林肠溶片 急性脑梗死 炎症介质 

分 类 号：R3[医药卫生—基础医学] R743.33